The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's disease

Alzheimer's Research & Therapy
Craig W RitchieAlistair Burns

Abstract

This commentary discusses the implications of disease-modifying treatments for Alzheimer's disease which seem likely to appear in the next few years and results from a meeting of British experts in neurodegenerative diseases in Edinburgh. The availability of such treatments would help change public and professional attitudes and accelerate engagement with the prodromal and preclinical populations who might benefit from them. However, this would require an updated understanding of Alzheimer's disease, namely the important distinction between Alzheimer's disease and Alzheimer's dementia. Since treatments are likely to be most effective in the early stages, identification of clinically relevant brain changes (for example, amyloid burden using imaging or cerebrospinal fluid biomarkers) will be crucial. While current biomarkers could be useful in identifying eligibility for new therapies, trial data are not available to aid decisions about stopping or continuing treatment in clinical practice. Therefore, effective monitoring of safety and effectiveness when these treatments are introduced into clinical practice will be necessary to inform wide-scale use. Equity of access is key but there is a tension between universal access for eve...Continue Reading

References

Dec 20, 2005·Lancet Neurology·Lawrence J WhalleyGeraldine McNeill
Jul 9, 2010·Lancet Neurology·Francesca MangialascheMiia Kivipelto
Nov 1, 2012·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Anna H Noel-StorrRupert McShane
Apr 5, 2015·Trends in Pharmacological Sciences·Kaj BlennowHenrik Zetterberg
Dec 20, 2015·The Lancet. Psychiatry·Craig W RitchieUNKNOWN European Prevention of Alzheimer's Dementia (EPAD) Consortium
Sep 2, 2016·Nature·Jeff SevignyAlfred Sandrock
Sep 2, 2016·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Randall J BatemanUNKNOWN DIAN-TU Pharma Consortium for the Dominantly Inherited Alzheimer Network
Sep 25, 2016·BMJ : British Medical Journal·Geva GreenfieldAzeem Majeed
Apr 5, 2017·Brain : a Journal of Neurology·John Hardy, Bart De Strooper
Aug 17, 2016·Alzheimer's & Dementia : Translational Research & Clinical Interventions·Jeffrey CummingsGaram Lee
Jul 26, 2015·Alzheimer's & Dementia : Translational Research & Clinical Interventions·Karen RitchieNikolaos Scarmeas

❮ Previous
Next ❯

Citations

Feb 28, 2019·Health Expectations : an International Journal of Public Participation in Health Care and Health Policy·Julie WatsonCharlotte Clarke
Jul 13, 2019·Alzheimer's & Dementia : Translational Research & Clinical Interventions·Rui MauricioUNKNOWN Therapeutics for Dementia Consortium
Oct 20, 2018·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Giovanni B FrisoniNicola Raffa
May 22, 2018·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Shana D StitesJason Karlawish
Aug 21, 2020·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Giovanni B FrisoniCraig Ritchie
Jun 21, 2018·The Cochrane Database of Systematic Reviews·Jacqueline S Birks, Richard J Harvey
Mar 19, 2019·Journal of Alzheimer's Disease : JAD·Jens Bohlken, Karel Kostev
May 11, 2019·Journal of Global Health·Tamlyn Watermeyer, Clara Calia
Jul 30, 2018·Journal of Alzheimer's Disease : JAD·Jens Bohlken, Karel Kostev
Sep 26, 2020·Practical Neurology·Magdalena A KolankoParesh A Malhotra
Aug 25, 2020·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Soeren MattkeMark Hanson
Oct 8, 2020·Der Nervenarzt·Lucrezia HausnerUNKNOWN Deutsches Netzwerk Gedächtnisambulanzen
Jan 23, 2021·BMJ : British Medical Journal·William Stewart
Feb 9, 2021·Frontiers in Neurology·James E GalvinIvana Rubino
Aug 14, 2019·Expert Systems with Applications·Magda BucholcKongFatt Wong-Lin
May 11, 2021·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Andrew J AschenbrennerAndre Strydom
Sep 27, 2021·Sociology of Health & Illness·Natassia Brenman, Richard Milne

❮ Previous
Next ❯

Software Mentioned

DIAN
TU

Related Concepts

Related Feeds

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Related Papers

Current Neurology and Neuroscience Reports
Peter W SchofieldYun Ming Yong
Annals of the New York Academy of Sciences
Natalie S Ryan, Nick C Fox
Clinical Medicine : Journal of the Royal College of Physicians of London
Robert BriggsDesmond O'Neill
© 2022 Meta ULC. All rights reserved